Yazar "Wu, X." için Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed listeleme
-
ENGOT-EN9/LEAP-001: A PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB PLUS LENVATINIB COMPARED WITH CHEMOTHERAPY IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Randall, L.; Marth, C.; Vulsteke, C.; Rubio, M. Jesus; Makker, V.; Braicu, I.; McNeish, I.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S.; Lee, J.; Pignata, S. (2020) -
ENGOT-en9/LEAP-001: A phase III, randomized, active-controlled, open-label study of pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin for newly diagnosed advanced or recurrent endometrial cancer
Marth, C.; Vulsteke, C.; Rubio, M. J. R.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Madry, R.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S.; Lee, J.; Pignata, S. (2020) -
ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Marth, C.; Vulsteke, C.; Rubio, M. J.; Makker, V.; Braicu, E. I.; McNeish, I. A.; Radoslaw, M.; Ayhan, A.; Hasegawa, K.; Wu, X.; Dutta, L.; Xu, C.; Keefe, S. M.; Lee, J.; Pıgnata, S. (2019) -
ENGOT-Ov65/KEYNOTE-B96: Phase III, Randomized, Double-Blind Study Of Pembrolizumab Vs Placebo Plus Paclitaxel With Optional Bevacizumab For Platinum-Resistant Recurrent Ovarian Cancer
Colombo, N.; Coleman, R. L.; Wu, X.; Kose, F.; Wenham, R.; Sebastianelli, A.; Hasegawa, K.; Zsiros, E.; Rouge, T. De La Motte; Bidzinski, M.; McNeish, I.; Sehouli, J.; Korach, J.; Debruyne, P. R.; Kim, J-W.; De Melo, A. C.; Peng, X.; Bogusz, A. M.; Yamada, K.; Monk, B. J. (2022)